Clinical Trials Logo

Filter by:
NCT ID: NCT03495830 Recruiting - Clinical trials for Carotid Artery Stenosis

Stratification of Patient With Carotid Disease

TAXINOMISIS
Start date: March 29, 2018
Phase:
Study type: Observational

Introduction: Taxinomisis trial is part of the Taxinomisis project. The concept of the Taxinomisis project is to stratify carotid artery disease relying on new modern data corresponding to contemporary patients based on information from longitudinal studies. Taxinomisis trial will validate this tool and adjust such stratification. Initial step of the project is characterization of symptomatic and asymptomatic carotid atherosclerotic plaque lesions, identification of risk and susceptibility factors through the exploitation of longitudinal cohort data and multiomics and disintegration of carotid artery disease phenotypes into endotypes through joint modeling of multipleomics data sets and systems medicine approaches. Finally such stratification model will be validated and adjusted in the Taxinomisis clinical trial.

NCT ID: NCT03485560 Not yet recruiting - Psoriasis Clinical Trials

Revitalization of Damaged Skin Due to Chronic Skin Diseases

Start date: May 1, 2018
Phase: Early Phase 1
Study type: Interventional

Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.

NCT ID: NCT03484065 Recruiting - Clinical trials for Afibrinogenemia, Congenital

Quality of Life in Patients With Congenital Afibrinogenemia

QualyAFIB
Start date: June 2016
Phase:
Study type: Observational

The aim of this observational study is to evaluate the quality of life in patients with congenital afibrinogenemia using the Haemo-QoL SF for kids and the Haem-A-QoL for adult patients.

NCT ID: NCT03481764 Recruiting - Febrile Seizure Clinical Trials

Anthropogenetic Variability in the Group of Individuals With Febrile Seizures

Start date: September 2015
Phase:
Study type: Observational

Febrile seizures (FS) are the most common neurological disorder in chilhood and are a great stress for parents due to their dramatic clinical appearance. Using HRC-test (test for determination of homozygously recessive characteristics in humans) we analyzed presence, distribution, and individual combination of 20 selected genetically controlled morpho-physiological traits among FS patients and control to determine a possible deviation in the homozygosity level and genetic loads in the group of affected children and whether there is a predisposition to the occurrence of FS.

NCT ID: NCT03466411 Not yet recruiting - Crohn's Disease Clinical Trials

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

GALAXI
Start date: April 13, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this program is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

NCT ID: NCT03460782 Available - Glioblastoma Clinical Trials

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Start date: n/a
Phase: N/A
Study type: Expanded Access

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

NCT ID: NCT03444012 Recruiting - Clinical trials for ACS (Acute Coronary Syndrome)

ADHERE-S (NIS Brilique)

Start date: March 5, 2018
Phase:
Study type: Observational

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

NCT ID: NCT03398148 Recruiting - Ulcerative Colitis Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

Start date: March 7, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

NCT ID: NCT03377699 Recruiting - Diabetes Clinical Trials

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes

EXPECT
Start date: November 22, 2017
Phase: Phase 3
Study type: Interventional

The investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use. In this study the medicine insulin degludec is compared to another medicine called insulin detemir. Participants will either get insulin degludec or insulin detemir and take it together with a medicine called insulin aspart - which treatment participants get is decided by chance. Participants will get pre-filled insulin pens. Participants will need to take blood sugar measurements several times a day. The study will last between 10 and 25 months depending on whether participants are already pregnant when they join the study. The number of visits and the tests ( for example blood and urine samples and ultrasound scans) the participants will have also depends on whether they are pregnant at study start

NCT ID: NCT03350737 Recruiting - Clinical trials for Chronic Stable Angina

Coronary Arteriogenetic Heparinized Exercise

CARHEXA
Start date: February 1, 2013
Phase: N/A
Study type: Interventional

This study evaluates the addition of heparin to a 2-week cycle of physical rehabilitation in the treatment of refractory angina. Half of the patients will undergo heparin-primed physical rehabilitation, while the other half will undergo only physical rehabilitation.